Cargando…

One-Year Safety and Efficacy Study of Arformoterol Tartrate in Patients With Moderate to Severe COPD

BACKGROUND: Arformoterol tartrate (arformoterol, 15 μg bid) is a nebulized long-acting β(2)-agonist approved for maintenance treatment of COPD. METHODS: This was a multicenter, double-blind, randomized, placebo-controlled study. Patients (aged ≥ 40 years with baseline FEV(1) ≤ 65% predicted, FEV(1)...

Descripción completa

Detalles Bibliográficos
Autores principales:	Donohue, James F., Hanania, Nicola A., Make, Barry, Miles, Matthew C., Mahler, Donald A., Curry, Lisa, Tosiello, Robert, Wheeler, Alistair, Tashkin, Donald P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American College of Chest Physicians 2014
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4251615/ https://www.ncbi.nlm.nih.gov/pubmed/25451347 http://dx.doi.org/10.1378/chest.14-0117

Ejemplares similares

Long-term health-related quality-of-life and symptom response profiles with arformoterol in COPD: results from a 52-week trial
por: Donohue, James F, et al.
Publicado: (2018)

Role of arformoterol in the management of COPD
por: King, Paul
Publicado: (2008)

Hospital readmissions following initiation of nebulized arformoterol tartrate or nebulized short-acting beta-agonists among inpatients treated for COPD
por: Bollu, Vamsi, et al.
Publicado: (2013)

Health resource utilization for inpatients with COPD treated with nebulized arformoterol or nebulized formoterol
por: Ganapathy, Vaidyanathan, et al.
Publicado: (2017)

Acute bronchodilator responsiveness and health outcomes in COPD patients in the UPLIFT trial
por: Hanania, Nicola A, et al.
Publicado: (2011)

Dose selection for glycopyrrolate/eFlow(®) phase III clinical studies: results from GOLDEN (Glycopyrrolate for Obstructive Lung Disease via Electronic Nebulizer) phase II dose-finding studies
por: Donohue, James F., et al.
Publicado: (2017)

Revefenacin: A Once-Daily, Long-Acting Bronchodilator For Nebulized Treatment Of COPD
por: Donohue, James F, et al.
Publicado: (2019)

Effect of background long-acting beta(2)-agonist therapy on the efficacy and safety of a novel, nebulized glycopyrrolate in subjects with moderate-to-very-severe COPD
por: Kerwin, Edward M, et al.
Publicado: (2018)

Smoking cessation in COPD: confronting the challenge
por: Tashkin, Donald P.
Publicado: (2021)

A review of nebulized drug delivery in COPD
por: Tashkin, Donald P
Publicado: (2016)

Preventing and managing exacerbations in COPD – critical appraisal of the role of tiotropium
por: Tashkin, Donald P
Publicado: (2010)

Acute bronchodilator responses decline progressively over 4 years in patients with moderate to very severe COPD
por: Tashkin, Donald P, et al.
Publicado: (2014)

A comparative study of efficacy and safety of arformoterol and salbutamol nebulization as rescue therapy in acute non-severe asthma
por: Das, Sibes K., et al.
Publicado: (2011)

Early efficacy of budesonide/formoterol in patients with moderate-to-very-severe COPD
por: Calverley, Peter M, et al.
Publicado: (2016)

Long-term safety and efficacy of formoterol fumarate inhalation solution in patients with moderate-to-severe COPD
por: Hanania, Nicola A, et al.
Publicado: (2018)

Targeting IL-5 in COPD
por: Narendra, Dharani K, et al.
Publicado: (2019)

Flupentixol tartrate
por: Yamuna, Thammarse S., et al.
Publicado: (2014)

Effects of mometasone furoate/formoterol fumarate fixed-dose combination formulation on chronic obstructive pulmonary disease (COPD): results from a 52-week Phase III trial in subjects with moderate-to-very severe COPD
por: Doherty, Dennis E, et al.
Publicado: (2012)

Medication management patterns among Medicare beneficiaries with chronic obstructive pulmonary disease who initiate nebulized arformoterol treatment
por: Celli, Bartolome R, et al.
Publicado: (2019)

Optimizing safety of COPD treatments: role of the nurse practitioner
por: Spencer, Pamela, et al.
Publicado: (2013)

Impact of baseline clinical features on outcomes of nebulized glycopyrrolate therapy in COPD
por: Tashkin, Donald P., et al.
Publicado: (2021)

Exacerbation frequency and course of COPD
por: Halpin, David MG, et al.
Publicado: (2012)

Revisiting the Use of Antibiotics to Prevent COPD Exacerbation: Is Doxycycline the Answer?
por: Adrish, Muhammad, et al.
Publicado: (2023)

Tiotropium HandiHaler(®) in the treatment of COPD: A safety review
por: Kesten, Steven, et al.
Publicado: (2009)

The Saudi guidelines for chronic obstructive pulmonary disease: A fresh “Real-World” approach to COPD
por: Hanania, Nicola A.
Publicado: (2014)

Tiotropium HandiHaler(®) and Respimat(®) in COPD: a pooled safety analysis
por: Halpin, David MG, et al.
Publicado: (2015)

Re‐evaluation of l(+)‐tartaric acid (E 334), sodium tartrates (E 335), potassium tartrates (E 336), potassium sodium tartrate (E 337) and calcium tartrate (E 354) as food additives
por: Younes, Maged, et al.
Publicado: (2020)

The role of combination therapy with corticosteroids and long-acting β(2)-agonists in the prevention of exacerbations in COPD
por: Cazzola, Mario, et al.
Publicado: (2006)

Tartrate of Morphia as an Agent for Hypodermic Injection
por: Stuart, John A. Erskine
Publicado: (1879)

Novel Anti-Inflammatory Approaches to COPD
por: Cazzola, Mario, et al.
Publicado: (2023)

Bis(melaminium) tartrate dihydrate
por: Su, Hong, et al.
Publicado: (2009)

The Treatment of Rhinosporidium by Antimony Tartrate
por: Wright, Robert E.
Publicado: (1923)

Tartrate of Soda as a Purgative
por: Delioux, M.
Publicado: (1853)

Pharmacotherapies in Older Adults with COPD: Challenges and Opportunities
por: Matera, Maria Gabriella, et al.
Publicado: (2023)

(R)-Doxylaminium (R,R)-tartrate
por: Dayananda, A.S., et al.
Publicado: (2012)

Adverse health consequences in COPD patients with rapid decline in FEV(1 )- evidence from the UPLIFT trial
por: Kesten, Steven, et al.
Publicado: (2011)

Effect of SGRQ-Defined Chronic Bronchitis at Baseline on Treatment Outcomes in Patients with COPD Receiving Nebulized Glycopyrrolate
por: Tashkin, Donald P, et al.
Publicado: (2021)

Efficacy and safety of a novel, nebulized glycopyrrolate for the treatment of COPD: effect of baseline disease severity and age; pooled analysis of GOLDEN 3 and GOLDEN 4
por: Ohar, Jill, et al.
Publicado: (2018)

Effect of mesenchymal stromal cell infusions on lung function in COPD patients with high CRP levels
por: Weiss, Daniel J., et al.
Publicado: (2021)

A Simplified Score to Quantify Comorbidity in COPD
por: Putcha, Nirupama, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_5b9uiagrkjp523pe2uqv6ot77e